BioXcel Therapeutics (BTAI) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioXcel Therapeutics (BTAI) PT Lowered to $7 at BofA Securities
March 13, 2024 6:13 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "BioXcel announced a 4Q23 update as the company continues to finalize the clinical programs (see report) designed... More
